Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Novartis Mitsubishi Tanabe Pharma Corporation |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00239798 |
This study will evaluate the safety and efficacy of FTY720 combined with cyclosporine and corticosteroids in patients receiving a kidney transplant.
Condition | Intervention | Phase |
---|---|---|
Renal Transplantation |
Drug: FTY720 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A 24-Month Extension of a One-Year, Multicenter, Double Blinded Double Dummy, Randomized Study to Evaluate the Safety and Efficacy of Two Doses of FTY720 Combined With Full-Dose Cyclosporine, USP [Modified] (Novartis Brand) and Steroids Versus Mycophenolate Mofetil Combined With Full-Dose Cyclosporine, USP [Modified] (Novartis Brand) and Steroids, in Adult De Novo Renal Transplant Recipients |
Estimated Enrollment: | 255 |
Study Start Date: | November 2004 |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Inclusion Criteria
Exclusion Criteria
Study ID Numbers: | CFTY720A2218E1 |
Study First Received: | October 13, 2005 |
Last Updated: | May 30, 2006 |
ClinicalTrials.gov Identifier: | NCT00239798 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Transplantation, kidney, organ transplant |
Cyclosporine Immunologic Factors Fingolimod |
Mycophenolate mofetil Immunosuppressive Agents Cyclosporins |
Immunologic Factors Fingolimod Physiological Effects of Drugs Immunosuppressive Agents Pharmacologic Actions |